1Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth[ J]. Nature, 1974, 249(453) : 123 - 127.
2Ribatti D, Vacca A, Rusnati M, et al. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies [ J ]. Cytokine Growth Factor Rev, 2007, 18 ( 3 - 4) : 327 -334.
4Seno M, Iwane M, Sasada R, et al. Monoclonal antibodies against human basic fibroblast growth factor[J]. Hybridoma, 1989, 8(2) : 209 -221.
5Reilly TM, Taylor DS, Herblin WF, et al. Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo[J].Biochem Biophys Res Commun, 1989, 164(2) : 736 -743.
6Matsuzaki K, Yoshitake Y, Matuo Y, et al. Monoclonat antibodies against heparin-binding growth factor Ⅱ/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis [J].Proc Natl Acad Sci USA, 1989, 86(24) : 9911 -9915.
7Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor [ J ]. Cancer Res, 1991,51 ( 22 ) : 6180 - 6184.
8Aonuma M, Yoshitake Y, Nishikawa K, et al. Different antitumor activities of anti-bFGF neutralizing antibodies: heparin-binding domain provides an inefficient epitope for neutralization in vivo[J]. Anticancer Res, 1999, 19(5B) : 4039 -4044.
